Does a biotech startup need a fractional CIO?
A biotech company usually needs a fractional CIO once it holds valuable research data, plans GxP-regulated work or faces investor and partner diligence. The role owns IT strategy, data integrity, validated-system planning, IP protection and vendor oversight part time. It fits pre-commercial companies that need executive judgment on these risks but not a full-time CIO.
Why biotech IT is different
In most companies, IT supports the business. In biotech, data is the business. Experimental results, sequences, assay data and regulatory records are the asset investors are funding, and losing, corrupting or leaking them can set a program back by months.
That raises the stakes on decisions an early team often makes informally: which electronic lab notebook to buy, where instrument data lands, who can delete files, and which outside collaborators get access.
What a fractional CIO owns in a biotech
- A roadmap that matches IT to the science and the clinical and regulatory timeline
- Data architecture: where research, instrument and quality data live, and how they are backed up and retained
- Planning for GxP systems before they are needed, including which systems will fall under FDA electronic records rules
- IP protection: access control, collaborator sharing, departing-employee procedures and AI tool policy
- Vendor and MSP oversight, including quality agreements where systems are regulated
- Security and IT evidence for investor, partner and acquirer diligence
The regulatory piece: plan early, not late
FDA's 21 CFR Part 11 governs electronic records and signatures used in place of paper for regulated activities. FDA's Part 11 scope and application guidance says the agency interprets the rule narrowly and exercises enforcement discretion on some requirements, such as validation, audit trails and record copying, but still enforces controls such as system access limits, authority checks and electronic signature requirements, and still expects compliance with the underlying predicate rules.
The practical lesson is that a system chosen casually in discovery can become a regulated system later. A fractional CIO helps your team decide which systems will need validation and audit trails, and buys or configures them accordingly so you are not re-platforming before an IND or a partner audit.
Where the role stops
A fractional CIO is not your quality unit. Decisions on GxP scope, validation acceptance and regulatory strategy belong to quality and regulatory leaders. The CIO's job is to make sure the technology, vendors and records can support those decisions, and to translate between scientists, quality staff and IT providers.
Day-to-day support such as laptops, accounts and help desk usually sits with a managed IT provider that the fractional CIO directs and holds accountable.
What the first 90 days should produce
A useful first quarter ends with a written inventory of systems, data locations and vendors; a short list of the risks that matter most to your programs and your investors; and a roadmap that sequences IT work against your scientific and regulatory milestones.
You should also have clear rules for who can access research data, how collaborators share files, and what happens to data and accounts when people leave. Those basics protect IP and are usually among the first things a diligence team asks about.
Common follow-up questions
When should a biotech bring in a fractional CIO?
Common triggers are a financing round with technical diligence, the first GxP or clinical activity, a move into lab space with instruments and networks, a first major collaboration that requires data sharing, or a security incident. Earlier is cheaper, because system choices are easier to make right than to unwind.
Is a fractional CIO the same as a computer system validation consultant?
No. A validation consultant executes and documents validation for specific systems. A fractional CIO sets the overall technology strategy, decides which systems you need and how they fit together, and manages the vendors. Many companies use both, with the CIO coordinating the work.
Does a biotech need its own IT staff?
Early-stage biotechs often do not. A managed IT provider can run daily operations while a fractional CIO provides leadership. Internal IT hires usually make sense later, when lab operations, sites or regulated systems grow to the point that on-site, full-time coverage is needed.
LAN Service Group provides IT strategy and fractional CIO-style leadership, managed IT and GxP-regulated IT for life-science and biotech companies.
Talk to LAN Service Group (888) 281-7243